The patient’s extraordinarily high PSA level (>1000 ng/mL) was not caused by prostate cancer. The imaging (likely MRI and bone scan) revealed widespread osteoblastic metastases covering nearly the entire skeleton—dense, sclerotic lesions in the spine, pelvis, ribs, and long bones. This pattern, combined with the PSA elevation, pointed to metastatic prostate carcinoma that had been silently progressing for years.
Prostate cancer is notorious for producing osteoblastic (bone-forming) metastases, which elevate PSA dramatically even in the absence of urinary symptoms. A PSA >1000 ng/mL almost always indicates stage IV disease with extensive bone involvement; levels >100 ng/mL have >90% positive predictive value for metastases. The patient’s prior good health masked the cancer’s insidious spread—common in ~15% of newly diagnosed cases that present with metastases despite no prior symptoms.
Two weeks later, the urologist delivered the diagnosis: metastatic castration-resistant prostate cancer (mCRPC) was unlikely at this stage; more probably de novo metastatic hormone-sensitive prostate cancer (mHSPC). A biopsy confirmed Gleason 4+5=9 adenocarcinoma. The tears came from the sudden realization that his proactive screening, while catching the disease, had uncovered an advanced stage with median survival of ~42–60 months even with modern therapy (androgen deprivation therapy + novel hormonal agents + chemotherapy).
He had not died young, but the horizon had shortened. The “lively smile” would return intermittently during treatment, but the future was now measured in scans, not decades.
Full clinical correlation (1848 text reference): Neill & Smith’s 1848 compendium predates PSA (discovered 1979) and modern imaging, but describes “scirrhous prostate” with “ossification of remote bones” as a fatal cachectic state. The historical term aligns with modern blastic metastases from prostate adenocarcinoma—the same disease, just named differently before PSA and MRI existed.
0 Comments